CAS No. :	1968-05-4
Formula :	C₁₇H₁₄N₂
M.W :	246.31
SMILES Code :	C1(CC2=CNC3=C2C=CC=C3)=CNC4=C1C=CC=C4
Synonyms :	DIM; Arundine; HB 236
MDL No. :	MFCD00195766
InChI Key :	VFTRKSBEFQDZKX-UHFFFAOYSA-N
Pubchem ID :	3071

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H315-H319-H335-H412
Precautionary Statements:	P261-P273-P305+P351+P338

Prdx-2 mutants	100 µM	24 hours	Reduced mitochondrial ROS levels	Antioxidants (Basel). 2022 May 11;11(5):950.
MCF-7 human breast cancer cells	10 µM	1 hour	To study the genome-wide binding profiles of DIM on ERα and AHR. DIM–ERα-bound regions were enriched for an AHRE motif, suggesting co-recruitment of ERα and AHR to target genes.	Int J Mol Sci. 2023 Sep 26;24(19):14578.
H1975 non-small cell lung cancer cells	20 and 50 µM	1, 2, and 3 days	DIM inhibited the growth of non-small cell lung cancer cells expressing the L858R+T790M EGFR mutation and reduced EGFR phosphorylation.	Cancer Lett. 2010 Sep 1;295(1):59-68.
H1650 non-small cell lung cancer cells	20 and 50 µM	1, 2, and 3 days	DIM inhibited the growth of non-small cell lung cancer cells expressing the delE746-A750 EGFR mutation and reduced EGFR phosphorylation.	Cancer Lett. 2010 Sep 1;295(1):59-68.
U87MG glioma cells	20 and 30 µM	1, 2, and 3 days	DIM inhibited the growth of EGFRvIII-expressing glioma cells and reduced the expression of EGFRvIII and Met.	Cancer Lett. 2010 Sep 1;295(1):59-68.
H4 glioma cells	20 and 30 µM	1, 2, and 3 days	DIM inhibited the growth of EGFRvIII-expressing glioma cells and reduced the expression of EGFRvIII and Met.	Cancer Lett. 2010 Sep 1;295(1):59-68.
MCF-7 breast cancer cells	10 and 20 µM	1, 2, and 3 days	DIM inhibited the growth of EGFRvIII-expressing breast cancer cells, but the effect was less pronounced than in MDA-MB-361 cells.	Cancer Lett. 2010 Sep 1;295(1):59-68.
MDA-MB-361 breast cancer cells	10 and 20 µM	1, 2, and 3 days	DIM inhibited the growth of EGFRvIII-expressing breast cancer cells and reduced the expression of EGFRvIII and ErbB2.	Cancer Lett. 2010 Sep 1;295(1):59-68.
Primary HSCs	10 μg/mL	15 days	To evaluate the effect of DIM on primary HSC activation, results showed that DIM inhibited the TGF-β/Smad signaling pathway by down-regulating miR-21 expression, thereby suppressing the self-activation process of primary HSCs.	Br J Pharmacol. 2013 Oct;170(3):649-60.
Wild-type N2 worms	100 µM	24 hours	Reduced oxidative stress and maintained mitochondrial function	Antioxidants (Basel). 2022 May 11;11(5):950.
HSC-T6 cells	10 μg/mL	24 hours	To evaluate the effect of DIM on HSC-T6 cell activation, results showed that DIM inhibited the TGF-β/Smad signaling pathway by down-regulating miR-21 expression, thereby suppressing HSC-T6 cell activation.	Br J Pharmacol. 2013 Oct;170(3):649-60.
Peritoneal macrophages	10 µM	24 hours	To investigate the effect of DIM on LPS-induced peritoneal macrophage activation. Results showed that DIM pretreatment significantly reduced LPS-induced TNF-α secretion.	Br J Pharmacol. 2015 Apr;172(8):2133-47.
RAW264.7 macrophages	10 µM	24 hours	To investigate the effect of DIM on LPS-induced macrophage activation. Results showed that DIM pretreatment significantly reduced LPS-induced TNF-α secretion and expression of macrophage activation markers (CD80, CD86, and CD40).	Br J Pharmacol. 2015 Apr;172(8):2133-47.
Huh7 cells	0, 20, 40, 60, 80, 120 µM	24 hours	DIM significantly suppressed Huh7 cell growth and proliferation in a concentration-dependent manner.	Cells. 2021 May 12;10(5):1178.
Hep3B cells	0, 20, 40, 60, 80, 120 µM	24 hours	DIM significantly suppressed Hep3B cell growth and proliferation in a concentration-dependent manner.	Cells. 2021 May 12;10(5):1178.
Human endometrial Ishikawa cancer cells	0.1 µM	24 hours	Restrained E2 or CYP-induced cell invasion	Int J Mol Sci. 2018 Jan 8;19(1):189.
Human endometrial Ishikawa cancer cells	0.1 µM	24 hours	Inhibited E2 or CYP-induced cell migration	Int J Mol Sci. 2018 Jan 8;19(1):189.
Human endometrial Ishikawa cancer cells	0.1 µM	24 hours	Suppressed E2 or CYP-induced epithelial-mesenchymal transition (EMT)	Int J Mol Sci. 2018 Jan 8;19(1):189.
MDA-MB-231	5, 10, 25, 40 µM	24-72 hours	DIM alone or in combination with Taxotere significantly inhibited the growth of breast cancer cells, with inhibition rates reaching 75-90%.	Int J Cancer. 2011 Oct 1;129(7):1781-91.
Rheumatoid arthritis fibroblast-like synoviocytes (RA-FLSs)	0, 20, 40, 60, 80 µM	24hours and 48 hours	To evaluate the effect of DIM on the viability of RA-FLSs, results showed DIM inhibited cell viability in a dose-dependent manner after 48h	Front Immunol. 2019 Jul 23;10:1620.
SGC-7901 gastric cancer cells	0-120 µM	24hours to 48 hours	DIM significantly inhibited the proliferation of SGC-7901 gastric cancer cells and activated STIM1-mediated SOCE by upregulating STIM1 and decreasing ER Ca2+ level, inducing apoptosis and autophagy.	Int J Biol Sci. 2021 Mar 19;17(5):1217-1233.
BGC-823 gastric cancer cells	0-120 µM	24hours to 48 hours	DIM significantly inhibited the proliferation of BGC-823 gastric cancer cells and activated STIM1-mediated SOCE by upregulating STIM1 and decreasing ER Ca2+ level, inducing apoptosis and autophagy.	Int J Biol Sci. 2021 Mar 19;17(5):1217-1233.
HT-22 cells	10–80 µM	30 minutes	DIM protected hippocampal neuronal cells against oxidative stress-induced apoptosis by regulating the expression of apoptosis-related proteins.	Antioxidants (Basel). 2019 Dec 18;9(1):3.
BM-derived MDSCs	10 µM, 20 µM, 40 µM, 80 µM	4 days	DIM suppressed the induced ratio of BM-MDSCs in a concentration-dependent manner, including both G-MDSCs and M-MDSCs subsets. Additionally, DIM treatment decreased the mRNA levels of Arg1 and iNOS in BM-MDSCs and partially abrogated the inhibitory effect of BM-MDSCs on the proliferation of CD4+ and CD8+ T cells.	Chin Med. 2022 Jun 30;17(1):81.
HepG2 cells	1-50 µM	4 hours	To investigate the effect of DIM on HIF-1α protein levels under hypoxic conditions. Results showed that DIM was effective at concentrations as low as 1 μM and completely inhibited HIF-1α expression at 50 μM.	Biochem Pharmacol. 2008 May 1;75(9):1858-67.
MDA-MB-231 cells	1-50 µM	4 hours	To investigate the effect of DIM on HIF-1α protein levels under hypoxic conditions. Results showed that DIM was effective at concentrations as low as 1 μM and completely inhibited HIF-1α expression at 50 μM.	Biochem Pharmacol. 2008 May 1;75(9):1858-67.
Human umbilical cord mesenchymal stem cells (hucMSCs)	50 µM	48 hours	To evaluate the effect of DIM on the stemness of hucMSCs, results showed that DIM dose-dependently induced the expression of Oct4, Nanog, Sox2, and Sall4.	Theranostics. 2017 Apr 10;7(6):1674-1688.
KYSE150 cells	0, 20, 40, 60 µM	48 hours	DIM inhibited migration and invasion of KYSE150 cells, downregulated mesenchymal cell markers β-Catenin, Vimentin and Slug, and upregulated epithelial cell marker Claudin-1	J Exp Clin Cancer Res. 2020 Jun 16;39(1):113.
TE1 cells	0, 20, 40, 60 µM	48 hours	DIM inhibited migration and invasion of TE1 cells, downregulated mesenchymal cell markers β-Catenin, Vimentin and Slug, and upregulated epithelial cell marker Claudin-1	J Exp Clin Cancer Res. 2020 Jun 16;39(1):113.
Human endometrial Ishikawa cancer cells	0.1 µM	6 days	Inhibited E2 or CYP-induced cell proliferation	Int J Mol Sci. 2018 Jan 8;19(1):189.
MCF-7 human breast cancer cells	10 µM	6 hours	To study the transcriptomic changes regulated by DIM via ERα and AHR. DIM treatment resulted in 446 differentially expressed genes, including upregulation of AHR target genes CYP1A1 and CYP1B1.	Int J Mol Sci. 2023 Sep 26;24(19):14578.
Mouse primary hippocampal cells	0.01, 0.1, 1, 10 µM	6 hours ischoursemia followed by 18 hours reoxygenation	DIM exhibited neuroprotective effects by inhibiting ischemia-induced apoptosis and autophagy, accompanied by a decrease in AhR/CYP1A1 signaling and an increase in HDAC activity.	Apoptosis. 2019 Jun;24(5-6):435-452.
Mouse primary hippocampal cells	0.01-10 µM	6 hours ischoursemia followed by 18 hours reoxygenation	DIM inhibited ischemia-induced apoptosis and autophagy, decreased AhR/CYP1A1 signaling, and increased HDAC activity	Apoptosis. 2019 Jun;24(5-6):435-452.
Rheumatoid arthritis fibroblast-like synoviocytes (RA-FLSs)	0, 25, 50 µM	6-12hours (migration) and 12-24hours (invasion)	To evaluate the effect of DIM on migration and invasion of RA-FLSs, results showed DIM significantly reduced migratory and invasion capacity of RA-FLSs	Front Immunol. 2019 Jul 23;10:1620.
SKBR3	25 or 40 µM	72 hours	DIM treatment significantly reduced FoxM1 mRNA levels and inhibited cell growth.	Int J Cancer. 2011 Oct 1;129(7):1781-91.
MDA-MB-468	25 or 40 µM	72 hours	DIM treatment significantly reduced FoxM1 mRNA levels and inhibited cell growth.	Int J Cancer. 2011 Oct 1;129(7):1781-91.
MCF-7	25 or 40 µM	72 hours	DIM treatment significantly reduced FoxM1 mRNA levels and inhibited cell growth.	Int J Cancer. 2011 Oct 1;129(7):1781-91.
Human endometrial Ishikawa cancer cells	0.1 µM	72 hours	Suppressed E2 or CYP-induced metastasis-related gene expression	Int J Mol Sci. 2018 Jan 8;19(1):189.
Human endometrial Ishikawa cancer cells	0.1 µM	72 hours	Inhibited E2 or CYP-induced EMT-related gene expression	Int J Mol Sci. 2018 Jan 8;19(1):189.

Wistar rats	Perinatal asphyxia model	Intraperitoneal injection	0.1, 10 or 100 mg/kg	First administration 30 minutes after HI, followed by additional doses at 24, 48 and 72 hours	DIM reduces brain damage induced by perinatal asphyxia by inhibiting AhR and NMDA signaling, restores brain weight and neuronal number, and inhibits apoptosis and oxidative stress	Apoptosis. 2020 Oct;25(9-10):747-762
C57BL/6 mice	Adjuvant-induced arthritis (AIA) model	Oral gavage	10 mg/kg	Once daily for 31 consecutive days	To evaluate the effect of DIM on arthritis severity in AIA mice, results showed DIM alleviated arthritis severity and pathological features	Front Immunol. 2019 Jul 23;10:1620.
BALB/C nude mice	Esophageal squamous cell carcinoma model	Gavage	10 mg/kg/day	Once daily for 4 weeks	DIM inhibited tumor growth and metastasis, downregulated AHR, RhoA, ROCK1, COX2 and mesenchymal cell markers, and upregulated epithelial cell marker Claudin-1	J Exp Clin Cancer Res. 2020 Jun 16;39(1):113.
ICR mice	Scopolamine-induced memory impairment model	Oral	10 or 20 mg/kg	Once daily for three consecutive days	DIM improved scopolamine-induced memory impairment by protecting hippocampal neuronal cells against oxidative damage.	Antioxidants (Basel). 2019 Dec 18;9(1):3.
Caenorhabditis elegans	Reproductively aged model	Oral feeding	100 μM	24 hours	Maintained oocyte quality and reproductive capacity	Antioxidants (Basel). 2022 May 11;11(5):950.
BALB/c mice	4T1 breast cancer model	Intraperitoneal injection	2, 5, 10 mg/kg	Three times a week for two weeks	DIM treatment significantly inhibited tumor growth and tumor weight in a dose-dependent manner and reduced the percentage of MDSCs in bone marrow, blood, spleen, and tumor tissues. Furthermore, DIM treatment increased the percentage of CD4+ and CD8+ T cells in blood, spleen, and tumor, and elevated the level of IFN-γ in tumor tissue.	Chin Med. 2022 Jun 30;17(1):81.
Female C57BL/6 mice	Unpredictable chronic mild stress (UCMS)-induced depressive-like behaviors model	Oral (mixed in peanut butter)	20 mg/kg	Daily administration for 3 weeks (prevention experiment) or 4 weeks (reversal experiment)	To evaluate the preventive and reversal effects of DIM and 1,4-DHNA on UCMS-induced depressive-like behaviors. Results showed that DIM and 1,4-DHNA could prevent and reverse UCMS-induced anhedonia-like behavior with little to no effect on anxiety levels and spatial learning.	J Affect Disord. 2022 Jul 15;309:201-210
ICR SCID mice	Breast cancer xenograft model	Oral gavage	3.5 mg/day/animal	Once daily for 3 weeks	DIM alone or in combination with Taxotere significantly inhibited tumor growth, with inhibition rates of 40% and 80%, respectively.	Int J Cancer. 2011 Oct 1;129(7):1781-91.
C57BL/6 mice	D-galactosamine/Lipopolysaccharide (GalN/LPS)-induced acute liver failure model	Intraperitoneal injection	40 mg/kg	Two doses, 24 hours and 2 hours before GalN/LPS injection	To investigate the protective effect of DIM on GalN/LPS-induced acute liver failure. Results showed that DIM pretreatment significantly improved survival rate, reduced serum ALT levels and liver tissue damage, and decreased levels of pro-inflammatory cytokines (TNF-α, IL-6, and CCL2).	Br J Pharmacol. 2015 Apr;172(8):2133-47.
BALB/c mice	RFP-expressing orthotopic breast cancer model derived from 4T1 CSCs	Intratumoral injection	5 mg/kg	Once daily for 10 days	E-DDMSNP significantly inhibited tumor growth and metastasis, prolonging survival time	J Nanobiotechnology. 2024 May 25;22(1):285.
ICR mice	Thioacetamide-induced hepatic fibrosis model	Intraperitoneal injection	50 mg/kg	Twice weekly for 8 weeks	To evaluate the therapeutic effect of DIM on thioacetamide-induced hepatic fibrosis, results showed that DIM attenuated liver fibrosis by down-regulating miR-21 expression and inhibiting the TGF-β signaling pathway.	Br J Pharmacol. 2013 Oct;170(3):649-60.

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

{[proInfo.proName]}

CAS No.: 1968-05-4

{[proInfo.proName]}

CAS No.: 1968-05-4

Alternative Products

Product Details of 3,3'-Diindolylmethane

Safety of 3,3'-Diindolylmethane

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed